드러그인포 약품요약정보

허가정보

항목

내용

청구코드(KD코드)
비급여점검코드
상한금액

비급여
[상병코드조회]
[질병코드조회]

빠른조회


요약정보	[효능] [용법] [금기] [신중투여] [이상반응]

상세정보	[효능] [용법] [경고] [금기] [신중투여] [이상반응] [일반주의] [상호작용] [임산부] [수유부] [소아] [고령자] [신장애환자] [간장애환자] [적용주의] [과량투여] [임상검사치] [보관] [기타]

제품성상

딸기향이 있는 담적색의 단맛이 있는 시럽제 [제형정보 확인]

포장·유통단위

100ml

효능효과

[적응증 별 검색]

- 감기 또는 알레르기성 및 혈관 운동성 비염에 의한 다음 증상의 완화 : 재채기, 콧물, 코막힘, 눈물
- 부비동염에 의한 비충혈의 일시적 완화

용법용량

* 절대 임의복용하지 마시고 반드시 의사 또는 약사와 상담하시기 바랍니다.

[처방약어]
성인 : 보통 1회 5~10ml, 1일 3~4회 식중 또는 식후에 복용한다.
소아 : 체중에 따라 다음과 같이 식중 또는 식후에 복용한다.
신생아에게는 투여하지 않는다.
41kg이상(성인) : 1회 5~10ml, 1일 3~4회
21~41kg(4~12세) : 1회 5ml, 1일 3~4회
16~20kg(2~4세) : 1회 3.75ml, 1일 3~4회
11~15kg(7개월~2세) : 1회 2.5ml, 1일 3~4회
5~10kg(1~6개월) : 1회 1.25ml, 1일 3~4회

[BMI지수 계산] [Body Surface Area 계산] [Cockcroft-Gault GFR 계산] [MDRD GFR 계산]

주요약물 상호작용

[조회]

금기

신생아 (중추신경자극효과가 역전될 위험이 있다.)
본제에 과민성인 환자
본제는 염산페닐프로판올아민을 함유하고 있으므로 염산페닐프로판올아민을 함유한 다른 약물(감기약, 비염용약, 진해거담제 등)을 투여중인 환자에는 투여하지 않는다.
급성천식발작, 중증의 고혈압, 중증의 심혈관계 질환환자
MAO억제제를 투여중이거나 투여를 중지한지 2주 이내인 환자

신중투여

녹내장, 고혈압, 심장질환, 관상동맥질환, 당뇨병, 갑상선 기능항진증, 전립선 비대로 인한 배뇨곤란시에는 투여하지 않는게 바람직하나 꼭 필요한 경우에는 의사의 지시에 따라 복용한다.
천식, 폐기종, 만성기관지염 등 호흡곤란 환자
7세 이하의 소아
임부 또는 가임부, 수유부

이상반응

정신신경계 : 졸음, 출혈성뇌졸중, 어지러움, 불면증, 불안, 심한 두통, 신경과민을 일으킬 수 있다.
순환기계 : 심계항진, 경미한 혈압강하를 일으킬 수 있다.
소화기계 : 구토, 구역, 변비, 식욕부진, 상복부불쾌감이 나타날 수 있다.
기타 : 발진, 발적, 배뇨장애, 일과성 자극통, 작열감, 구갈, 발한이 나타날 수 있다.
과량 복용시 급성중독(환각 및 경련), 신경과민, 현기, 불면증 등을 일으킬 수 있으므로 권장량 이상을 초과하지 않는다.

소아에게 특히 흥분이 나타날 수 있다.

[주요 이상반응정보]

상호작용

알코올, 중추신경억제제(수면제, 진정제, 안정제), 혈압강하제, MAO 저해제 등의 항우울약과의 병용을 피한다.

Related FDA Approved Drug

기준 성분:PHENYLPROPANOLAMINE HYDROCHLORIDE
BIPHETAP (BROMPHENIRAMINE MALEATE; PHENYLPROPANOLAMINE HYDROCHLORIDE)
BROMANATE (BROMPHENIRAMINE MALEATE; PHENYLPROPANOLAMINE HYDROCHLORIDE)
BROMANATE DC (BROMPHENIRAMINE MALEATE; CODEINE PHOSPHATE; PHENYLPROPANOLAMINE HYDROCHLORIDE)
BROMATAPP (BROMPHENIRAMINE MALEATE; PHENYLPROPANOLAMINE HYDROCHLORIDE)
CHLOROHENIRAMINE MALEATE AND PHENYLPROPANOLAMINE HYDROCHLORIDE (CHLORPHENIRAMINE MALEATE; PHENYLPROPANOLAMINE HYDROCHLORIDE)
CHLORPHENIRAMINE MALEATE AND PHENYLPROPANOLAMINE HYDROCHLORIDE (CHLORPHENIRAMINE MALEATE; PHENYLPROPANOLAMINE HYDROCHLORIDE)
CODAMINE (HYDROCODONE BITARTRATE; PHENYLPROPANOLAMINE HYDROCHLORIDE)
COLD CAPSULE IV (CHLORPHENIRAMINE MALEATE; PHENYLPROPANOLAMINE HYDROCHLORIDE)
COLD CAPSULE V (CHLORPHENIRAMINE MALEATE; PHENYLPROPANOLAMINE HYDROCHLORIDE)
CONTAC (CHLORPHENIRAMINE MALEATE; PHENYLPROPANOLAMINE HYDROCHLORIDE)
CONTAC 12 HOUR (CHLORPHENIRAMINE MALEATE; PHENYLPROPANOLAMINE HYDROCHLORIDE)
DEMAZIN (CHLORPHENIRAMINE MALEATE; PHENYLPROPANOLAMINE HYDROCHLORIDE)
DIMETANE-DC (BROMPHENIRAMINE MALEATE; CODEINE PHOSPHATE; PHENYLPROPANOLAMINE HYDROCHLORIDE)
DIMETAPP (BROMPHENIRAMINE MALEATE; PHENYLPROPANOLAMINE HYDROCHLORIDE)
DRIZE (CHLORPHENIRAMINE MALEATE; PHENYLPROPANOLAMINE HYDROCHLORIDE)
HYCOMINE (HYDROCODONE BITARTRATE; PHENYLPROPANOLAMINE HYDROCHLORIDE)
HYCOMINE PEDIATRIC (HYDROCODONE BITARTRATE; PHENYLPROPANOLAMINE HYDROCHLORIDE)
MYPHETANE DC (BROMPHENIRAMINE MALEATE; CODEINE PHOSPHATE; PHENYLPROPANOLAMINE HYDROCHLORIDE)
ORNADE (CHLORPHENIRAMINE MALEATE; PHENYLPROPANOLAMINE HYDROCHLORIDE)
PHENYLPROPANOLAMINE HYDROCHLORIDE W/ CHLORPHENIRAMINE MALEATE (CHLORPHENIRAMINE MALEATE; PHENYLPROPANOLAMINE HYDROCHLORIDE)
TAVIST-D (CLEMASTINE FUMARATE; PHENYLPROPANOLAMINE HYDROCHLORIDE)
TRIAMINIC-12 (CHLORPHENIRAMINE MALEATE; PHENYLPROPANOLAMINE HYDROCHLORIDE)
기준 성분:PHENYLEPHRINE HYDROCHLORIDE
CYCLOMYDRIL (CYCLOPENTOLATE HYDROCHLORIDE; PHENYLEPHRINE HYDROCHLORIDE)
PHENERGAN VC (PHENYLEPHRINE HYDROCHLORIDE; PROMETHAZINE HYDROCHLORIDE)
PHENERGAN VC W/ CODEINE (CODEINE PHOSPHATE; PHENYLEPHRINE HYDROCHLORIDE; PROMETHAZINE HYDROCHLORIDE)
PHENYLEPHRINE HYDROCHLORIDE AND PROMETHAZINE HYDROCHLORIDE (PHENYLEPHRINE HYDROCHLORIDE; PROMETHAZINE HYDROCHLORIDE)
PHERAZINE VC (PHENYLEPHRINE HYDROCHLORIDE; PROMETHAZINE HYDROCHLORIDE)
PHERAZINE VC W/ CODEINE (CODEINE PHOSPHATE; PHENYLEPHRINE HYDROCHLORIDE; PROMETHAZINE HYDROCHLORIDE)
PREFRIN-A (PHENYLEPHRINE HYDROCHLORIDE; PYRILAMINE MALEATE)
PROMETH HYDROCHLORIDE,PHENYLEPHRINE HYDROCHLORIDE W/CODEINE PHOSPHATE (CODEINE PHOSPHATE; PHENYLEPHRINE HYDROCHLORIDE; PROMETHAZINE HYDROCHLORIDE)
PROMETH VC PLAIN (PHENYLEPHRINE HYDROCHLORIDE; PROMETHAZINE HYDROCHLORIDE)
PROMETH VC W/ CODEINE (CODEINE PHOSPHATE; PHENYLEPHRINE HYDROCHLORIDE; PROMETHAZINE HYDROCHLORIDE)
PROMETHAZINE HYDROCHLORIDE AND PHENYLEPHRINE HYDROCHLORIDE (PHENYLEPHRINE HYDROCHLORIDE; PROMETHAZINE HYDROCHLORIDE)
PROMETHAZINE VC PLAIN (PHENYLEPHRINE HYDROCHLORIDE; PROMETHAZINE HYDROCHLORIDE)
PROMETHAZINE VC W/ CODEINE (CODEINE PHOSPHATE; PHENYLEPHRINE HYDROCHLORIDE; PROMETHAZINE HYDROCHLORIDE)
기준 성분:BROMPHENIRAMINE MALEATE
BROMANATE DM (BROMPHENIRAMINE MALEATE; DEXTROMETHORPHAN HYDROBROMIDE; PSEUDOEPHEDRINE HYDROCHLORIDE)
BROMFED-DM (BROMPHENIRAMINE MALEATE; DEXTROMETHORPHAN HYDROBROMIDE; PSEUDOEPHEDRINE HYDROCHLORIDE)
BROMPHENIRAMINE MALEATE (BROMPHENIRAMINE MALEATE)
BROMPHERIL (DEXBROMPHENIRAMINE MALEATE; PSEUDOEPHEDRINE SULFATE)
DIMETANE (BROMPHENIRAMINE MALEATE)
DIMETANE-DX (BROMPHENIRAMINE MALEATE; DEXTROMETHORPHAN HYDROBROMIDE; PSEUDOEPHEDRINE HYDROCHLORIDE)
DIMETANE-TEN (BROMPHENIRAMINE MALEATE)
DISOBROM (DEXBROMPHENIRAMINE MALEATE; PSEUDOEPHEDRINE SULFATE)
DISOMER (DEXBROMPHENIRAMINE MALEATE)
DISOPHROL (DEXBROMPHENIRAMINE MALEATE; PSEUDOEPHEDRINE SULFATE)
DRIXORAL (DEXBROMPHENIRAMINE MALEATE; PSEUDOEPHEDRINE SULFATE)
DRIXORAL PLUS (ACETAMINOPHEN; DEXBROMPHENIRAMINE MALEATE; PSEUDOEPHEDRINE SULFATE)
EFIDAC 24 PSEUDOEPHEDRINE HYDROCHLORIDE/BROMPHENIRAMINE MALEATE (BROMPHENIRAMINE MALEATE; PSEUDOEPHEDRINE HYDROCHLORIDE)
RESPORAL (DEXBROMPHENIRAMINE MALEATE; PSEUDOEPHEDRINE SULFATE)
VELTANE (BROMPHENIRAMINE MALEATE)

정보요약

드럭인포 의약품 요약/상세정보

코드 및 분류정보

항목	내용
BIT 약효분류	비염 & 콧물약 (Decongestants & Nasal Prep.)
복지부분류코드	141 (항히스타민제 )
Drugs By Indication	[전체보기]
Drugs By Classification	[전체보기]

제품정보

항목	내용
청구코드(KD코드) 비급여점검코드 상한금액	비급여 [상병코드조회] [질병코드집 다운로드]
제품성상	딸기향이 있는 담적색의 단맛이 있는 시럽제 [제형정보 확인]
포장·유통단위	100ml
보관방법	기밀용기, 실온 보관

복약정보

항목

내용

LACTmed 바로가기

[바로가기]

약리작용

유료정보입니다.

복약지도

유료정보입니다.

임부에대한투여

*	전체임신 기간별로 여러등급이 존재할 수 있으며 가장 위험도가 높은 정보만 보여집니다. 단, 복합제의 경우 모든 복합제성분에 대한 임부투여등급이 표시된것은 절대 아니며 표시된것중에 가장 위험도가 높은 정보만 나타납니다.

FDA : C등급

*	상기 임부투여에 대한 정보는 전산처리 되면서 입력 오류 가능성이 존재합니다. 오류 가능성을 최소화하기 위하여 많은 노력을 기울이고 있으나, 그 정확성에 대하여 확신을 드릴 수 없습니다. 이에 대해 회사는 책임을 지지 않습니다.
*	반드시 공신력 있는 문헌을 다시 한번 참고 하시기 바라며 의사 또는 약사의 판단에 따라 투여여부가 결정되어야 합니다.

Pharmacokinetics

유료정보입니다.

병용금기 및 연령대금기 근거조회

[병용금기 및 연령대금기 근거조회]

복약라벨

이미지

복약설명

변비가 생길수 있습니다.

어지러움이 있을수 있습니다.

*	복약이미지는 모든 복약지도 사항을 표시한것은 아니며, 추가적으로 업데이트되거나 수정될 수 있습니다.
*	복약이미지의 표시여부는 실제 약물복용시 중요도에 따른것은 아니며 단순히 허가정보상 키워드를 기준으로 등록되었습니다.
*	귀하가 복약이미지 정보를 신뢰함은 전적으로 귀하의 책임입니다. 드럭인포는 이에 대한 어떠한 보증도 하지 않습니다.

보관상 주의

조제시 주의

심사정보

항목	내용
DUR 관련 고시	[병용연령금기 의약품 / 임부금기 의약품 / 비용효과적 함량 의약품 / 안전성 관련 급여중지 의약품]

학술정보

항목	내용
DUR (의약품사용평가)	병용금기 : 고시된 병용금기 내용은 없습니다. [상호작용/병용금기검색] 연령대금기 : 고시된 연령금기 내용은 없습니다. [연령대금기상세검색]
Mechanism of Action	Brompheniramine에 대한 Mechanism_Of_Action 정보 Brompheniramine works by acting as an antagonist of the H1 histamine receptors. It also functions as a moderately effective anticholingeric agent, likely an antimuscarinic agent similar to other common antihistamines such as diphenhydramine. Its effects on the cholinergic system may include side-effects such as drowsiness, sedation, dry mouth, dry throat, blurred vision, and increased heart rate. Phenylephrine에 대한 Mechanism_Of_Action 정보 Phenylephrine produces its ophthalmic and systemic actions by acting on alpha 1 adrenergic receptors in the pupillary dilator muscle and the vascular smooth musle, resulting in contraction of the dilator muscle and contraction of the smooth muscle in the arterioles of the conjunctiva and peripheral vasoconstriction. Phenylephrine decreases nasal congestion by acting on alpha 1 adrenergic receptors in the arterioles of the nasal mucosa to produce constriction. Phenylpropanolamine에 대한 Mechanism_Of_Action 정보 Phenylpropanolamine acts directly on alpha- and, to a lesser degree, beta-adrenergic receptors in the mucosa of the respiratory tract. Stimulation of alpha-adrenergic receptors produces vasoconstriction, reduces tissue hyperemia, edema, and nasal congestion, and increases nasal airway patency. PPA indirectly stimulates beta-receptors, producing tachycardia and a positive inotropic effect.
Pharmacology	Brompheniramine에 대한 Pharmacology 정보 Brompheniramine is an antihistaminergic medication of the propylamine class. It is a first-generation antihistamine. In allergic reactions an allergen interacts with and cross-links surface IgE antibodies on mast cells and basophils. Once the mast cell-antibody-antigen complex is formed, a complex series of events occurs that eventually leads to cell-degranulation and the release of histamine (and other chemical mediators) from the mast cell or basophil. Once released, histamine can react with local or widespread tissues through histamine receptors. Histamine, acting on H₁-receptors, produces pruritis, vasodilatation, hypotension, flushing, headache, tachycardia, and bronchoconstriction. Histamine also increases vascular permeability and potentiates pain. Brompheniramine is a histamine H1 antagonist (or more correctly, an inverse histamine agonist) of the alkylamine class. It provides effective, temporary relief of sneezing, watery and itchy eyes, and runny nose due to hay fever and other upper respiratory allergies. Phenylephrine에 대한 Pharmacology 정보 Phenylephrine is a powerful vasoconstrictor. It is used as a mydriatic, nasal decongestant, and cardiotonic agent. Phenylephrine is a postsynaptic alpha-receptor stimulant with little effect on the beta receptors of the heart. Parenteral administration of Phenylephrine causes a rise in systolic and diastolic pressures, cardiac output is slightly decreased and peripheral resistance is considerably increased, most vascular beds are constricted; renal, splanchnic, cutaneous, and limb blood flows are reduced but coronary blood flow is increased. Pulmonary vessels are constricted, and pulmonary arterial pressure is raised. This alpha receptor sympathetic agonist is also used locally because its vasoconstrictor and mydriatic action. Phenylpropanolamine에 대한 Pharmacology 정보 Phenylpropanolamine (PPA), a sympathomimetic agent structurally similar to pseudoephedrine, is used to treat nasal congestion. Phenylpropanolamine is found in appetite suppressant formulations and with guaifenesinin in cough-cold formulations. In 2000, the FDA requested that all drug companies discontinue marketing products containing phenylpropanolamine, due to an increased risk of hemorrhagic stroke in women who used phenylpropanolamine.
Metabolism	Brompheniramine에 대한 Metabolism 정보 # Phase_1_Metabolizing_Enzyme:Not Available Phenylephrine에 대한 Metabolism 정보 # Phase_1_Metabolizing_Enzyme:Monoamine oxidase type A (MAO-A) Phenylpropanolamine에 대한 Metabolism 정보 # Phase_1_Metabolizing_Enzyme:Monoamine oxidase type A (MAO-A)
Protein Binding	Brompheniramine에 대한 단백결합 정보 Not Available Phenylephrine에 대한 단백결합 정보 95% binding-plasma proteins Phenylpropanolamine에 대한 단백결합 정보 Not Available
Half-life	Brompheniramine에 대한 반감기 정보 Not Available Phenylephrine에 대한 반감기 정보 2.1 to 3.4 hours Phenylpropanolamine에 대한 반감기 정보 2.1 to 3.4 hours.
Absorption	Brompheniramine에 대한 Absorption 정보 Antihistamines are well absorbed from the gastrointestinal tract after oral administration. Phenylephrine에 대한 Absorption 정보 Reduced bioavailability (compared to pseudoephedrine) following oral administration due to significant first-pass metabolism. Phenylpropanolamine에 대한 Absorption 정보 Reduced bioavailability (about 38%) from gastrointestinal tract because of first pass metabolism by monoamine oxidase in the stomach and liver.
Pharmacokinetics	Brompheniramine Maleate의 약물동력학자료 최고효과 발현시간 : 3-9 시간 이내 최고혈중농도 발현시간 : 경구 : 2-5 시간 이내 작용지속시간 : 제형에 따라 큰 차이를 보임 대사 : 간대사 반감기 : 12-34 시간 소실 : 비활성대사체로 신배설 되며 2%가 변으로 소실됨 Phenylephrine HCl의 약물동력학자료 효과발현시간 근육주사, 피하주사 : 10~15분 이내 정맥주사 : 즉시 효과지속시간 근육주사 : 30분 ~ 2시간 정맥주사 : 15~30분 피하주사 : 1시간 대사 : Phenolic 포합체로 대사됨. Monoamine oxidase에 의해 간과 장에서 대사됨. 반감기 : 2.5 시간 소실 : 신배설 (90%) Phenylpropanolamine HCl의 약물동력학자료 흡수 : 경구 : 잘 흡수됨 생체내이용률 : 거의 100% 대사 : 간에서 norephedrine으로 대사됨 반감기 : 4.6-6.6 시간 소실 : 주로 미변화체로서(80-90%) 뇨를 통해 배설됨
Biotransformation	Brompheniramine에 대한 Biotransformation 정보 Hepatic (cytochrome P-450 system), some renal. Phenylephrine에 대한 Biotransformation 정보 Oral phenylephrine is extensively metabolised by monoamine oxidase, an enzyme which is present in the stomach and liver. Phenylpropanolamine에 대한 Biotransformation 정보 Hepatic
Toxicity	Brompheniramine에 대한 Toxicity 정보 Oral, rat: LD₅₀ = 318 mg/kg. Signs of overdose include fast or irregular heartbeat, mental or mood changes, tightness in the chest, and unusual tiredness or weakness. Phenylephrine에 대한 Toxicity 정보 Not Available Phenylpropanolamine에 대한 Toxicity 정보 May induce ventricular extrasystoles and short paroxysms of ventricular tachycardia, a sensation of fullness in the head and tingling of the extremities; LD₅₀=1490mg/kg (orally in rat)
Drug Interactions	Brompheniramine에 대한 Drug_Interactions 정보 Donepezil Possible antagonism of actionGalantamine Possible antagonism of actionRivastigmine Possible antagonism of action Phenylephrine에 대한 Drug_Interactions 정보 Alseroxylon Increased arterial pressureIsocarboxazid Increased arterial pressureDeserpidine Increased arterial pressureGuanethidine The agent decreases the effect of guanethidineRasagiline Increased arterial pressureMethyldopa Increased arterial pressureMidodrine Increased arterial pressurePargyline Increased arterial pressurePhenelzine Increased arterial pressureReserpine Increased arterial pressureTranylcypromine Increased arterial pressureOxytocin Possible marked increase of arterial pressureMethylergonovine Possible marked increase of arterial pressureLinezolid Possible increase of arterial pressureErgonovine Possible marked increase of arterial pressureTrimipramine The tricyclic increases the sympathomimetic effectProtriptyline The tricyclic increases the sympathomimetic effectNortriptyline The tricyclic increases the sympathomimetic effectClomipramine The tricyclic increases the sympathomimetic effectAmitriptyline The tricyclic increases the sympathomimetic effectAmoxapine The tricyclic increases the sympathomimetic effectDesipramine The tricyclic increases the sympathomimetic effectDoxepin The tricyclic increases the sympathomimetic effectImipramine The tricyclic increases the sympathomimetic effectMoclobemide Moclobemide increases the sympathomimetic effect Phenylpropanolamine에 대한 Drug_Interactions 정보 Acetophenazine Decreased anorexic effect, may increase psychotic symptomsChlorpromazine Decreased anorexic effect, may increase psychotic symptomsEthopropazine Decreased anorexic effect, may increase psychotic symptomsFluphenazine Decreased anorexic effect, may increase psychotic symptomsMethotrimeprazine Decreased anorexic effect, may increase psychotic symptomsGuanethidine The agent decreases the effect of guanethidineMesoridazine Decreased anorexic effect, may increase psychotic symptomsThioridazine Decreased anorexic effect, may increase psychotic symptomsMethdilazine Decreased anorexic effect, may increase psychotic symptomsTrimeprazine Decreased anorexic effect, may increase psychotic symptomsPropericiazine Decreased anorexic effect, may increase psychotic symptomsPerphenazine Decreased anorexic effect, may increase psychotic symptomsProchlorperazine Decreased anorexic effect, may increase psychotic symptomsPromazine Decreased anorexic effect, may increase psychotic symptomsPromethazine Decreased anorexic effect, may increase psychotic symptomsPropiomazine Decreased anorexic effect, may increase psychotic symptomsThiethylperazine Decreased anorexic effect, may increase psychotic symptomsTrifluoperazine Decreased anorexic effect, may increase psychotic symptomsTriflupromazine Decreased anorexic effect, may increase psychotic symptomsMoclobemide Moclobemide increases the sympathomimetic effectAmitriptyline The tricyclic increases the sympathomimetic effectAmoxapine The tricyclic increases the sympathomimetic effectBromocriptine The sympathomimetic increases the toxicity of bromocriptineClomipramine The tricyclic increases the sympathomimetic effectDesipramine The tricyclic increases the sympathomimetic effectDoxepin The tricyclic increases the sympathomimetic effectImipramine The tricyclic increases the sympathomimetic effectNortriptyline The tricyclic increases the sympathomimetic effectProtriptyline The tricyclic increases the sympathomimetic effectTrimipramine The tricyclic increases the sympathomimetic effectVenlafaxine Risk of serotoninergic syndromeFluvoxamine Risk of serotoninergic syndromeParoxetine Risk of serotoninergic syndromeFluoxetine Risk of serotoninergic syndromeAlseroxylon Increased arterial pressureDeserpidine Increased arterial pressureIsocarboxazid Increased arterial pressureLinezolid Possible increase of arterial pressureTranylcypromine Increased arterial pressureRasagiline Increased arterial pressureReserpine Increased arterial pressurePhenelzine Increased arterial pressurePargyline Increased arterial pressureMethyldopa Increased arterial pressureMidodrine Increased arterial pressure
CYP450 Drug Interaction	[CYP450 Table직접조회]
Food Interaction	Brompheniramine에 대한 Food Interaction 정보 Take with food.Avoid alcohol. Phenylephrine에 대한 Food Interaction 정보 Take without regard to meals. Phenylpropanolamine에 대한 Food Interaction 정보 Take without regard to meals.Limit caffeine intake.
Drug Target	[Drug Target]
Description	Brompheniramine에 대한 Description 정보 Histamine H1 antagonist used in treatment of allergies, rhinitis, and urticaria. [PubChem] Phenylephrine에 대한 Description 정보 An alpha-adrenergic agonist used as a mydriatic, nasal decongestant, and cardiotonic agent. [PubChem] Phenylpropanolamine에 대한 Description 정보 Phenylpropanolamine has been withdrawn in Canada. In November 2000, the Food and Drug Administration (FDA) issued a public health advisory against the use of the drug.
Dosage Form	Brompheniramine에 대한 Dosage_Form 정보 Not Available Phenylephrine에 대한 Dosage_Form 정보 Liquid IntramuscularLiquid IntravenousLiquid OphthalmicOintment TopicalSolution IntravenousSolution / drops OphthalmicStrip OralTablet Oral Phenylpropanolamine에 대한 Dosage_Form 정보 Not Available
Drug Category	Brompheniramine에 대한 Drug_Category 정보 Anti-Allergic AgentsHistamine H1 Antagonists Phenylephrine에 대한 Drug_Category 정보 Adrenergic alpha-AgonistsCardiotonic AgentsMydriaticsNasal DecongestantsSympathomimeticsVasoconstrictor Agents Phenylpropanolamine에 대한 Drug_Category 정보 Adrenergic alpha-AgonistsAppetite DepressantsNasal DecongestantsSympathomimetics
Smiles String Canonical	Brompheniramine에 대한 Smiles_String_canonical 정보 CN(C)CCC(C1=CC=C(Br)C=C1)C1=CC=CC=N1 Phenylephrine에 대한 Smiles_String_canonical 정보 CNCC(O)C1=CC(O)=CC=C1 Phenylpropanolamine에 대한 Smiles_String_canonical 정보 CC(N)C(O)C1=CC=CC=C1
Smiles String Isomeric	Brompheniramine에 대한 Smiles_String_isomeric 정보 CN(C)CC[C@H](C1=CC=C(Br)C=C1)C1=CC=CC=N1 Phenylephrine에 대한 Smiles_String_isomeric 정보 CNC[C@H](O)C1=CC(O)=CC=C1 Phenylpropanolamine에 대한 Smiles_String_isomeric 정보 C[C@@H](N)[C@@H](O)C1=CC=CC=C1
InChI Identifier	Brompheniramine에 대한 InChI_Identifier 정보 InChI=1/C16H19BrN2/c1-19(2)12-10-15(16-5-3-4-11-18-16)13-6-8-14(17)9-7-13/h3-9,11,15H,10,12H2,1-2H3 Phenylephrine에 대한 InChI_Identifier 정보 InChI=1/C9H13NO2/c1-10-6-9(12)7-3-2-4-8(11)5-7/h2-5,9-12H,6H2,1H3/t9-/m0/s1 Phenylpropanolamine에 대한 InChI_Identifier 정보 InChI=1/C9H13NO/c1-7(10)9(11)8-5-3-2-4-6-8/h2-7,9,11H,10H2,1H3/t7-,9-/m1/s1
Chemical IUPAC Name	Brompheniramine에 대한 Chemical_IUPAC_Name 정보 3-(4-bromophenyl)-N,N-dimethyl-3-pyridin-2-ylpropan-1-amine Phenylephrine에 대한 Chemical_IUPAC_Name 정보 3-[(1R)-1-hydroxy-2-methylaminoethyl]phenol Phenylpropanolamine에 대한 Chemical_IUPAC_Name 정보 (1S,2R)-2-amino-1-phenylpropan-1-ol
Drug-Induced Toxicity Related Proteins	MALEATE 의 Drug-Induced Toxicity Related Protein정보 Replated Protein:Intercellular adhesion molecule 1 Drug:maleate Toxicity:hepatic injury. [바로가기]

사용자컨텐츠

항목

내용

핵심 요약 정보